Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 3 |
2018 | 1 |
2019 | 1 |
2021 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet. 2021 Jul 10;398(10295):131-142. doi: 10.1016/S0140-6736(21)00580-8.
Lancet. 2021.
PMID: 34246347
Clinical Trial.
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK.
Thuss-Patience PC, et al. Among authors: harle yge ml.
Lancet Oncol. 2017 May;18(5):640-653. doi: 10.1016/S1470-2045(17)30111-0. Epub 2017 Mar 23.
Lancet Oncol. 2017.
PMID: 28343975
Clinical Trial.
Item in Clipboard
Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
Chen SC, Kagedal M, Gao Y, Wang B, Harle-Yge ML, Girish S, Jin J, Li C.
Chen SC, et al. Among authors: harle yge ml.
Cancer Chemother Pharmacol. 2018 Feb;81(2):421-422. doi: 10.1007/s00280-017-3488-1.
Cancer Chemother Pharmacol. 2018.
PMID: 29189914
Item in Clipboard
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
Chen SC, Kagedal M, Gao Y, Wang B, Harle-Yge ML, Girish S, Jin J, Li C.
Chen SC, et al. Among authors: harle yge ml.
Cancer Chemother Pharmacol. 2017 Dec;80(6):1147-1159. doi: 10.1007/s00280-017-3443-1. Epub 2017 Oct 17.
Cancer Chemother Pharmacol. 2017.
PMID: 29043411
Clinical Trial.
Item in Clipboard
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL.
Shah MA, et al. Among authors: harle yge ml.
Gastric Cancer. 2019 Jul;22(4):803-816. doi: 10.1007/s10120-018-00923-7. Epub 2019 Jan 31.
Gastric Cancer. 2019.
PMID: 30706247
Clinical Trial.
Item in Clipboard
A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
Li C, Agarwal P, Gibiansky E, Jin JY, Dent S, Gonçalves A, Nijem I, Strasak A, Harle-Yge ML, Chernyukhin N, LoRusso P, Girish S.
Li C, et al. Among authors: harle yge ml.
Clin Pharmacokinet. 2017 Sep;56(9):1069-1080. doi: 10.1007/s40262-016-0496-y.
Clin Pharmacokinet. 2017.
PMID: 27995530
Clinical Trial.
Item in Clipboard
Cite
Cite